JACOB BORDELON: Open Payments
NPI 1912489279 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,092 in 70 payments from 14 companies in 2025. Trend: 2023 $198 · 2024 $1,024 · 2025 $1,092
Food & beverage: $1,063Education: $29
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $454 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $137 |
| Janssen Biotech, Inc. | 8 | $130 |
| PFIZER INC. | 7 | $117 |
| Ardelyx, Inc. | 3 | $65 |
| GENZYME CORPORATION | 1 | $35 |
| Gilead Sciences, Inc. | 2 | $33 |
| Janssen Pharmaceuticals, Inc | 3 | $29 |
| QOL Medical, LLC | 1 | $20 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $16 |
Products named: RINVOQ, TREMFYA, LINZESS, ENTYVIO, SKYRIZI, IBSRELA, VELSIPITY, XELJANZ.
Industry payments across LA — which companies pay providers there.
